Penumbra is a medical devices business based in the US. Penumbra shares (PEN) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $208.65 – a decrease of 1.28% over the previous week. Penumbra employs 4,200 staff and has a trailing 12-month revenue of around $1.1 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $208.65 |
|---|---|
| 52-week range | $148.00 - $277.34 |
| 50-day moving average | $193.63 |
| 200-day moving average | $210.87 |
| Wall St. target price | $211.94 |
| PE ratio | 590.3428 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.35 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $208.65 from 2024-10-18
| 1 week (2024-10-14) | -1.28% |
|---|---|
| 1 month (2024-09-20) | 7.00% |
| 3 months (2024-07-19) | 9.89% |
| 6 months (2024-04-19) | 2.93% |
| 1 year (2023-10-20) | 1.53% |
|---|---|
| 2 years (2022-10-21) | 21.85% |
| 3 years (2021-10-21) | 278.5 |
| 5 years (2019-10-21) | 41.33% |
Valuing Penumbra stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Penumbra's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Penumbra's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 590x. In other words, Penumbra shares trade at around 590x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Penumbra's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $105.6 million.
The EBITDA is a measure of a Penumbra's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Gross profit TTM | $535.2 million |
| Return on assets TTM | 3.32% |
| Return on equity TTM | 1.28% |
| Profit margin | 1.26% |
| Book value | $29.90 |
| Market Capitalization | $8 billion |
TTM: trailing 12 months
We're not expecting Penumbra to pay a dividend over the next 12 months.
Penumbra's shares were split on a 10:1 basis on 15 November 2014 . So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Penumbra shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Penumbra shares which in turn could have impacted Penumbra's share price.
Over the last 12 months, Penumbra's shares have ranged in value from as little as $148 up to $277.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Penumbra's is 0.545. This would suggest that Penumbra's shares are less volatile than average (for this exchange).
Penumbra, Inc. , together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a commission-free platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.